2026년 2월 19일 · Unknown · financial · 출처 Yahoo Finance
This article first appeared on GuruFocus.
Revenue: CHF2.6 billion, representing an organic growth of 8.9%. Reported Growth in Swiss Francs: 4.1%, with a translation impact of around CHF100 million. Core EBIT Margin: 26.5% excluding currency headwinds; 25.2% including currency effects. Core Net Results: CHF478 million, with a net margin of 18.3%. Free Cash Flow: CHF290 million, representing 11.1% of net revenue. Core Gross Profit Margin: 70.1%. Capital Expenditure: CHF223 million, marking one of the strongest investment years. Dividend Proposal: CHF1 per share, a 5% increase from the prior year. EMEA Organic Growth: Above 11% for the full year. North America Organic Growth: 6.8% in the fourth quarter. Asia Pacific Organic Growth: Around 7% for the full year, with over 10% growth outside China. Latin America Organic Revenue Growth: Around 18% for the year.
Warning! GuruFocus has detected 5 Warning Signs with NVDA. Is SAUHF fairly valued? Test your thesis with our free DCF calculator.
Release Date: February 18, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Straumann Holding AG (SAUHF) achieved a strong revenue growth of CHF2.6 billion in 2025, representing an organic growth of 8.9%. The company launched a record number of new products in 2025, with the iEXCEL implant becoming the most successful implant launch in its history. Straumann Holding AG (SAUHF) reported a core EBIT margin increase to 26.5% at constant currency rates, demonstrating resilience and disciplined execution. The company expanded its market share in key segments, increasing its total share from 12.5% to 14% within the last 12 months. Straumann Holding AG (SAUHF) generated a free cash flow of CHF290 million, reflecting strong operating performance and effective working capital management.
Negative Points
The company faced currency and tariff headwinds, which impacted revenue growth in Swiss francs, resulting in a reported growth of only 4.1%. Performance in China was significantly impacted by a softer patient flow and distributor destocking behavior, particularly linked to the upcoming GDP process. The financial results were slightly lower compared to the prior year due to the effects of currency hedging and higher taxes. The transition of clear aligner production to Smartee has not yet had a meaningful impact on EBIT margin in 2025. The company experienced a visible impact on profitability due to FX effects, with revenue growth differing by around 480 basis points between local currencies and Swiss francs.
Story Continues
Q & A Highlights
Q: Can you provide insights into the sales phasing for 2026, especially considering the situation in China? A: Guillaume Daniellot, CEO: We expect the VBP process in China to occur in the second quarter, impacting the first half of the year. The growth rate for 2026 will likely be more weighted towards the second half, with North America expected to continue its positive trend due to stable macro conditions and strong execution.
Q: What should we expect regarding free cash flow in 2026? A: Isabelle Adelt, CFO: We anticipate a significant improvement in free cash flow due to lower CapEx levels, reduced working capital, and fewer non-core items. The completion of major investment cycles, such as the Curitiba factory, will contribute to this improvement.
Q: How did North America perform in Q4, and what are the expectations for 2026? A: Guillaume Daniellot, CEO: North America's growth was primarily volume-driven, with minimal price impact. We expect continued positive trends in 2026, supported by the success of the iEXCEL implants and stable DSO investments in marketing activities.
Q: Can you elaborate on the EMEA performance in Q4 and its sustainability? A: Guillaume Daniellot, CEO: EMEA showed strong growth across all segments, boosted by a January 2026 price increase and high digital equipment orders. We expect EMEA to maintain high single-digit to low double-digit growth in 2026, with a balanced performance across quarters.
Q: What are the expectations for the ClearCorrect business and its impact on margins? A: Isabelle Adelt, CFO: The transition to Smartee manufacturing will improve cost efficiency, with significant margin benefits expected in the second half of 2026. We aim to make ClearCorrect profitable over the next two years, supported by new product launches and increased growth rates.
Q: How do you see the prosthetics market evolving, and what role will DSOs play? A: Guillaume Daniellot, CEO: The shift to chairside solutions is driven by patient expectations for same-day treatments. DSOs will play a crucial role in adopting these workflows due to efficiency and profitability gains, although the transition will be gradual due to the conservative nature of dentistry.
Q: What is the outlook for China in 2026, considering the VBP process and destocking? A: Guillaume Daniellot, CEO: We expect a weaker first half due to a strong comparison base and ongoing destocking, but anticipate a recovery in the second half. The destocking impact should be less significant than in 2025, as distributor inventories are at minimal levels.
Q: Can you provide more details on the iOS business and its market share? A: Guillaume Daniellot, CEO: The iOS market is valued at just under CHF2 billion, with our market share now in double digits. We expect continued growth as we penetrate the GP segment and connect more clinicians to our Straumann Access platform, enhancing workflow efficiency and product adoption.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
View Comments